2019/1/2 – CRI Report

Investigation Report on China’s Recombinant Human Follitropin Market, 2018-2022

admin — Wed, 02 Jan 2019 02:40:11 +0000

Recombinant Human Follitropin Market Overview

According to CRI, as environmental pollution intensifies and Chinese people’s lifestyle changes, the incidence of infertility is increasing in China. In 2017, the incidence of infertility among married couples in China was 10%, more than double the 4.8% in 1984. It is estimated that about 15% to 20% women of childbearing age in China are troubled by infertility.

In China, as the biggest cause of female infertility, follicular dysplasia syndrome resulting from endocrine dysfunction accounts for over 40% of female infertility.

In China’s end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin beta, Recombinant Human Chorionic Gonadotropin, and Recombinant Human Lutropin alfa are taking the place of small-molecule chemicals.

Follicle-stimulating hormone (FSH) is a heterodimeric glycoprotein formed by the non-covalent binding of subunits alpha and beta. FSH, luteinizing hormone (LH), thyroid-stimulating hormone (TSH) and human chorionic gonadotropin (HCG) are collectively known as the glycoprotein hormones family.

They share the same alpha subunit but differ from each other in beta subunit which determines their biological activity. FSH has important medicinal value in reproductive health. It can promote ovulation for natural production or artificial insemination, and can also help produce ova for in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI).

According to CRI, the FSH products in China include Urofollitropin (u-FSH) extracted from urine and Recombinant Human Follitropin (rh-FSH). Due to high purity and stability, Recombinant Human Follitropin (rh-FSH) has great advantages on the market.

In China, Recombinant Human Follitropin has been approved (1) to treat anovulation (including polycystic ovary syndrome, PCOS) that cannot be cured by Clomiphene Citrate; and (2) to be used for superovulation and follicular development by assisted reproductive treatment such as in vitro fertilization-embryo transfer (IVF-ET), gamete intrafallopian transfer (GIFT), and intracytoplasmic sperm injection (ICSI).

Merck Serono’s Recombinant Human Follitropin (trade name: GONAL-f) was approved to be marketed in China in 2008, and GeneScience Pharmaceuticals Co., Ltd.’s Jinsaiheng was also approved in 2015.

By the end of 2018, all the Recombinant Human Follitropin products in China were produced by Merck Serono and GeneScience Pharmaceuticals Co., Ltd. The sales value of Recombinant Human Follitropin kept rising after the drug was launched in China, reaching about CNY 548 million in 2017.

It is expected that the incidence of infertility will continue to grow as environmental pollution intensifies and Chinese people’s lifestyle changes. Meanwhile, as the average childbearing age of Chinese women continues to rise and China’s family planning policy is loosened, many older women plan to have a second child, which will drive the demand for Recombinant Human Follitropin in China.

In the coming years, more companies’ generic Recombinant Human Follitropin will be launched in China.

Topics Covered:
– Situation of infertility in China
– Status of China’s Recombinant Human Follitropin market
– Competition on China’s Recombinant Human Follitropin market
– Prices of Recombinant Human Follitropin in China
– Factors influencing the development of China’s Recombinant Human Follitropin market
– Prospect of China’s Recombinant Human Follitropin market from 2018 to 2022
– Progress of Recombinant Human Follitropin in China

Investigation Report on China’s Recombinant Human Thrombopoietin (rhTPO) Market 2021-2025

The post Investigation Report on China’s Recombinant Human Follitropin Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Hydrotalcite Market, 2018-2022

admin — Wed, 02 Jan 2019 02:40:10 +0000

Description
The incidences of gastrointestinal diseases are rising in China with the development of China’s economy, the change of dietary habits and daily routines, and the intensification of environmental pollution. It is estimated that the number of patients with gastrointestinal diseases in China has exceeded 120 million, and is still growing, with the incidence of chronic gastritis hovering at 30%.
According to CRI’s market research, the top 5 chemical drugs for gastritis and peptic ulcer in China are all proton-pump inhibitors. Among them, the gastric mucosal protective agents represented by Hydrotalcite are featured by high safety, few side effects, and quick relief, and thus saw a growing market demand. Hydrotalcite is a gastric mucosal protective agent that can quickly neutralize gastric acid, reduce the stimulation and corrosion of gastric acid on the esophageal mucosa, and significantly relieve pains. It can also accelerate the healing of ulcers. Used to treat acute and chronic gastritis, reflux esophagitis, peptic ulcer, heartburn and stomach upset related to gastric acid, it can relieve the cardialgia, acid reflux, nausea, vomiting, abdominal distension and other symptoms caused by excessive gastric acid, and prevent the gastric mucosal lesions caused by nonsteroidal anti-inflammatory drugs.
In 2017, the market size of Hydrotalcite in China was close to CNY 110 million. The Hydrotalcite products in China are marketed in the dosage forms of suspension, tablets and granules. The market is dominated by the tablets.
By the end of 2018, more than 20 manufacturers have obtained the approval for Hydrotalcite production. However, China’s Hydrotalcite market is highly concentrated. In 2017, by sales value, more than 90% market share went to the top 5 market players, namely, Bayer, Chongqing Pharscin Pharmaceutical Co., Ltd., Sichuan Jewelland Pharmaceutical Co., Ltd., Hainan Health Care Laboratories Ltd., and Guangxi Nanning Baihui Pharmaceutical Group Co., Ltd. And Bayer alone took up a market share of over 80%.
With the quickening pace of life, the change of dietary habits and the intensification of environmental pollution, the number of patients with gastrointestinal diseases in China will continue to rise in the coming years, which promises certain growth potential for China’s Hydrotalcite market.

Topics Covered:
– Situation of gastrointestinal diseases in China
– Status of China’s Hydrotalcite market
– Competition on China’s Hydrotalcite market
– Prices of Hydrotalcite in China
– Major factors influencing the development of China’s Hydrotalcite market
– Prospect of China’s Hydrotalcite market, 2018-2022

https://www.cri-report.com/product/investigation-report-on-chinas-hydrotalcite-market-2021-2025/

The post Investigation Report on China’s Hydrotalcite Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Botulinum Toxin Type A Market, 2018-2022

admin — Wed, 02 Jan 2019 02:40:09 +0000

Description
As the most toxic one of the eight antigenic types of botulinum, Botulinum Toxin Type A can irreversibly unite with presynaptic membrane within one hour. The targeted striated muscle will be relaxed usually 48 to 72 hours after the injection of Botulinum Toxin Type A. And the effect is maximally visible seven to 14 days following injection. Such muscle relaxation usually lasts for three to six months but varies greatly among different people. For some people, it can last up to 18 months.
On Apr. 15, 2002, Botulinum Toxin Type A was approved by the FDA as a medical cosmetic that is injected to temporarily improve the appearance of moderate to severe glabellar lines. Later, some generic drugs appeared on the market. In addition to the imported Botulinum Toxin Type A (trade name: Botox) produced by Allergan, the Botulinum Toxin Type A products in China also include Botulinum Toxin Type A (trade name: Hengli) developed by Lanzhou Institute of Biological Products Co., Ltd.
In China, the medical use of Botulinum Toxin Type A is to treat adult blepharospasm and prosopospasm and some strabismuses, especially acute paralytic strabismus, concomitant strabismus, strabismus caused by endocrine diseases, and the strabismus that cannot be corrected surgically for those aged 12 and above. The incidence of facial neuropathy is increasing in China. Many people are attacked by prosopospasm when they are over-stressed or fatigued. Seeing global annual incidence of about 0.003%, facial neuropathy is more common in women than in men, and more common in middle-aged and elderly people than in people from other age groups.
However, more users of Botulinum Toxin Type A are women who pursue a thin face or less wrinkles. With more than 10 million cosmetic surgeries every year, the market size of medical beauty in China has exceeded USD 10 billion and is still growing. As the demand for Botulinum Toxin Type A is expanding, some medical institutions and beauty salons have begun to inject Botulinum Toxin Type A smuggled from South Korea, France, Germany, etc. for their customers. Although the Chinese government only approved the sale of Botox and Hengli, smuggled Botulinum Toxin Type A products are easily available in China.
It is expected that, with the development of China’s economy, the rise of income, and the change of consumption habit, Chinese people will spend more in medical beauty, and the market size of Botulinum Toxin Type A will continue to grow in China in the next few years.

Topics Covered:
– Status of China’s medical beauty market
– Sales of Botulinum Toxin Type A in China
– Competition on China’s Botulinum Toxin Type A market
– Major factors influencing the development of China’s Botulinum Toxin Type A market
– Prospect of China’s Botulinum Toxin Type A market from 2018 to 2022

The post Investigation Report on China’s Botulinum Toxin Type A Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Fibrin Sealant (Human) Market, 2018-2022

admin — Wed, 02 Jan 2019 02:40:09 +0000

China’s Fibrin Sealant (Human) Market

Fibrin sealant, also known as fibrin glue, is a biological product commonly used in surgery. Fibrin Sealant (Human) is a blood product that can help treat burn wounds, abdominal incisions in general surgery, incisions in liver surgery, and incisions in vascular surgery by stopping bleeding and covering and sealing wounds.

In China, the accidental deaths and burns rank only second to traffic injuries. And the traffic injuries also include many burns. The annual incidence of burns in China is about 1.5% to 2%, which means that about 20 million people suffer burns every year. And about 5% of the burn victims need hospitalization.

From Jan. to Sept. 2018, the number of people discharged from China’s medical and health institutions reached 185,577,000, increasing by 6.4% YOY, and a large proportion of the inpatients had surgery. The sales value of Fibrin Sealant (Human) has been rising since the drug was launched in China, reaching about CNY 144 million in 2017.

According to CRI’s market research, China’s Fibrin Sealant (Human) market is dominated by Shanghai RAAS Blood Products Co., Ltd. and Hualan Biological Engineering Inc., and the former has a market share of more than 90% by sales value.

Global Automotive Adhesives & Sealants Market Outlook 2030: Industry Insights & Opportunity Evaluation, 2019-2030

It is expected that in the next few years, with the lifestyle changes brought about by economic development and the rising incidences of various diseases caused by population aging, the number of surgical operations in China will continue to rise, which will help expand the market size of Fibrin Sealant (Human).

Topics Covered:
– Situation of surgical operations in China
– Status of China’s Fibrin Sealant (Human) market
– Competition on China’s Fibrin Sealant (Human) market
– Prices of Fibrin Sealant (Human) in China
– Factors influencing the development of China’s Fibrin Sealant (Human) market
– Prospect of China’s Fibrin Sealant (Human) market from 2018 to 2022

The post Investigation Report on China’s Fibrin Sealant (Human) Market, 2018-2022 first appeared on CRI Report.